🇺🇸 FDA

Drug profile · INN

sofosbuvir

EPCLUSA

approved J05AX15
US status
approved
Patents linked
2
News articles
0

Quick answer

sofosbuvir (EPCLUSA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sofosbuvir
Brand EPCLUSA
Route ORAL
Formulation PELLETS
ATC code J05AX15
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 10676498

    Processes for the preparation of sofosbuvir and intermediates thereof

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10214553

    Solid state forms of sofosbuvir

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is sofosbuvir?

sofosbuvir (EPCLUSA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sofosbuvir?

EPCLUSA is a marketed brand name for sofosbuvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sofosbuvir?

sofosbuvir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.